Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFβ that is critical for Vif function
© The Author(s) 2017
Received: 31 January 2017
Accepted: 8 March 2017
Published: 17 March 2017
HIV-1 Vif interacts with the cellular core-binding factor β (CBFβ) and counteracts the protective roles of certain human APOBEC3 (A3) proteins by targeting them for proteasomal degradation. Previous studies have identified some amino acids important for Vif–CBFβ interactions, and recently a co-crystal structure of a pentameric complex of HIV-1 Vif, CBFβ, Cul5, EloB, and EloC was resolved. However, a comprehensive analysis of Vif–CBFβ interactions that are important for Vif function has not been performed.
Here, we carried out double-alanine scanning mutagenesis of the first 60 amino acids of Vif and determined their effects on interaction with CBFβ and their ability to induce A3G degradation as well as rescue HIV-1 replication in the presence of A3G. We found that multiple Vif residues are involved in the extensive N-terminal Vif–CBFβ interaction and that the 5WQVMIVW11 region of Vif is the major determinant. A minimum of three alanine substitutions are required to completely abrogate the Vif–CBFβ interaction and Vif’s ability to rescue HIV-1 infectivity in the presence of A3G. Mutational analysis of CBFβ revealed that F68 and I55 residues are important and participate in a tripartite hydrophobic interaction with W5 of Vif to maintain a stable and functional Vif–CBFβ complex. We also determined that CBFβ amino acids 73WQGEQR78, which are not resolved in the structure of the pentameric complex, are not involved in interaction with HIV-1 Vif.
Our results provide detailed insight into the Vif–CBFβ interactions that are critical for Vif function and may contribute to the rational design of HIV-1 inhibitors that block Vif-mediated degradation of A3 proteins.
HIV-1 and other lentiviruses encode the accessory protein Vif that counteracts the antiviral activities of APOBEC3 (A3) proteins and is required for infection and propagation in primary CD4+ T cells and in non-permissive T cell lines (for recent reviews see Refs. [1, 2]). Vif neutralizes the inhibitory activities of A3 proteins by targeting them for polyubiquitination and proteasomal degradation by hijacking an E3 ubiquitin ligase complex .
Jager et al.  and Zhang et al.  recently reported that in addition to binding to cullin 5 (Cul5) and elongin B/C (EloB/C), Vif binds to the cellular core-binding factor β (CBFβ), and the Vif–CBFβ interaction is essential for inducing efficient degradation of A3 proteins, which inhibit HIV-1 replication in non-permissive cell types. CBFβ is an evolutionarily conserved non-DNA binding component of the mammalian runt-related transcription factors (RUNX 1-3), which are critical in hematopoiesis, T cell differentiation, and skeletal development [6, 7]. CBFβ is an allosteric regulator of RUNX proteins and has previously been reported to stabilize RUNX1 by preventing its ubiquitin-mediated degradation . Recently, CBFβ was proposed to play a critical role in stabilizing the intrinsically unstructured HIV-1 Vif and promoting formation of a well-ordered substrate receptor by facilitating local folding of the N-terminal Vif region [4, 5, 9–11].
Several reports have established that HIV-1 Vif interacts with CBFβ and have shown that CBFβ depletion hampers virus replication in cells expressing A3 proteins primarily by interfering with Vif’s ability to induce degradation of the A3 proteins [4, 5, 9]. HIV-1 Vif associates with CBFβ in human cells and recombinant CBFβ enhances Vif’s solubility, stability, and association with an E3 ubiquitin ligase complex [9, 10, 12–14]. Initially, the interaction interface was mapped to residues 15–126 of CBFβ [9, 15]; CBFβ amino acid F68 was then reported to be critical for stable HIV-1 Vif–CBFβ interaction . Subsequently, an X-ray crystal structure of five pentameric complexes, each containing CBFβ–Vif–EloB/C-Cul5, was determined . In the pentameric complex, HIV-1 Vif is tightly associated with CBFβ and interacts with both EloC and Cul5.
Determining the biological relevance of the critical residues of Vif that govern the specificity of the Vif–CBFβ interaction can facilitate our understanding of this important host–virus interaction. Additionally, elucidating this interaction at the molecular level can potentially assist in the design of inhibitors that block Vif–CBFβ binding and thereby interfere with Vif function. Previous mutational analyses identified several residues of Vif that were important for its interaction with CBFβ [10, 16–18]. Of particular relevance to this work, Fribourgh et al.  reported that deletion of the first 13 amino acids of Vif abolished the interaction of recombinant Vif with CBFβ, consistent with the crystal structure data, which showed that there are extensive interactions between the N-terminal hydrophobic anti-parallel β-strands of HIV-1 Vif and CBFβ .
To determine the functional importance of these extensive N-terminal HIV-1 Vif–CBFβ interactions, we analyzed double-alanine mutants of the first 60 amino acids of HIV-1 Vif and determined the effects of the mutations on CBFβ binding by co-immunoprecipitation. We found that 5WQVMIVW11 region of Vif is important for the Vif–CBFβ interaction, of which W5 is the most critical determinant. We also found that H27–H28 and D37–W38 influence CBFβ binding eventhough they are not at the CBFβ–Vif interface in the pentameric complex, suggesting that they indirectly affect the interaction with CBFβ. We also observed that CBFβ amino acids 73WQGEQR78, which are in close proximity to residues E45–S52 of Vif and are not resolved in the pentameric complex crystal structure, do not contribute to the Vif–CBFβ interaction. Finally, consistent with the crystal structure, our mutational analysis indicated that CBFβ amino acids I55 and F68 form a tripartite interaction with W5 of Vif that is critical for Vif function.
Identification of HIV-1 Vif determinants that are important for interaction with CBFβ
The pentameric structure  indicated that the Vif amino acids from W5–W11 are in close proximity to CBFβ amino acids N63–F68 and I55; each of the Vif amino acids is within 3.46–5.99 angstroms (Å) of the CBFβ amino acids, suggesting that any or all of these Vif–CBFβ interactions could be critical for Vif function. The importance of the W5–W11 amino acids of Vif is supported by a previous study  indicating that deleting the first 13 amino acids of Vif abolishes the interaction between Vif and CBFβ. Our results indicating that the double mutants W5A–Q6A and I9A–V10A disrupt the interaction with CBFβ, but the V7A–M8A and W11A mutants did not, indicated that some of these amino acids are critical for the interaction while others are less important. Surprisingly, our results showed that the H27A–H28A and D37A–W38A mutants severely hampered the interaction between Vif and CBFβ in our binding assay; these amino acids are 11–15 Å away from the nearest CBFβ amino acid (R151) in the pentameric structure and are not at the interaction interface (PDB:4N9F) . Analysis of the structure of Vif  suggested that W38, I57, I107, Y111, and F112 are involved in an extensive hydrophobic interaction that maintains the structural organization of the α-domain of HIV-1 Vif (Additional file 1: Supplementary Fig. S1), implying that they indirectly affect the interaction with CBFβ.
Our observations that the double mutants W5A–Q6A and I9A–V10A disrupt the interaction with CBFβ in cells provide functional insights into the recently reported structural information of the pentameric complex , which showed that amino acids 5WQVMIVW11 interact with CBFβ. We also found that amino acids E45–P58 of Vif, which forms a flexible loop , influenced the Vif–CBFβ interaction. Amino acids E45–S52 are in a position to potentially form direct interactions with amino acids W73–R78 of CBFβ. However, this region of CBFβ was not resolved in the pentameric complex ; thus, a potential direct interaction between these amino acids of Vif and CBFβ could not be verified or excluded based on the crystal structure. Finally, we also observed that N3A–R4A, Q12A–V13A, M16A–R17A, N19A–T20A, and R23A–L24A mutants exhibited a significantly higher efficiency of binding to CBFβ compared to WT Vif (Fig. 1b; values indicated in red); the potential biological significance of increased binding to CBFβ by these mutants was not further examined in these studies.
Effects of CBFβ-binding mutations on Vif’s ability to induce A3G degradation and rescue HIV-1 infectivity
Effect of reducing the level of CBFβ on the ability of Vif mutants to degrade A3G and rescue HIV-1 infectivity
Effect of Vif quadruple– and triple–alanine substitution mutations 5WQVM8 > 4A and 9IVW11 > 3A on interaction with CBFβ and A3G degradation
Next, we determined the effects of the quadruple– and triple–alanine substitution mutations in Vif on A3G degradation and infectivity (Fig. 4c–e). We found that both 5WQVM8 > A4 and 9IVW11 > A3 mutants failed to mediate A3G degradation (Fig. 4c, d) and rescue infectivity when viruses were produced in cells that co-expressed A3G (Fig. 4e). These data suggest that the N-terminal interaction between HIV-1 Vif and CBFβ is stabilized by hydrophobic interactions and at least three alanine substitutions are required to abolish the interaction between the anti-parallel β-strands of Vif and CBFβ .
73WQGEQR78 residues of CBFβ are not important for stable Vif–CBFβ interaction
We generated CBFβ mutants W73A–Q74A, G75A–E76A, and Q77A–R78A and determined their ability to interact with Vif (Fig. 5b, c). To examine the effects of these CBFβ double mutations on Vif binding, we first knocked down the endogenous CBFβ in 293T cells using an siRNA that binds to the 3′ untranslated region of the CBFβ mRNA; the efficiency of knockdown was >90% (Fig. 5b). We then expressed wild-type Flag-CBFβ or its mutants and determined the effects of the mutations on steady-state levels of Flag-A3G. We found that none of these CBFβ double mutants had a measurable effect on the interaction between CBFβ and Vif compared to wild-type CBFβ (Fig. 5b, c), suggesting that the 73WQGEQR78 residues are not required for the Vif–CBFβ interaction.
A tripartite interaction between I55 and F68 of CBFβ and W5 of Vif is critical for stable Vif–CBFβ binding
The list of host proteins in the Vif interactome is expanding and among these are EloB/C, CUL5, and CBFβ, which are essential for counteracting the antiviral activities of A3 proteins by targeting them for proteasomal degradation [4, 5, 10, 20–22]. Thus, the Vif–CBFβ interaction is a potential target for development of antiviral agents that interfere with Vif’s ability to induce degradation of A3 proteins. The recently reported pentameric crystal structure of Vif–CBFβ–CUL5–EloB/C has provided valuable structural information about this interaction , and has indicated that the interface is stable primarily due to extensive hydrophobic interactions involving a large surface area (4797 Å2). Although the extensive nature of this protein–protein interaction suggests that small molecules are unlikely to disrupt the Vif–CBFβ interaction, it is possible that specific determinants of this interaction are essential for Vif function, and such functionally relevant determinants could provide targets for antiviral drug development. In these studies, we sought to determine which Vif–CBFβ interactions are essential for Vif function by performing alanine scanning mutagenesis of the first 60 amino acids of Vif. Our results show that Vif residues 5WQVMIVW11 play a critical role in binding to CBFβ; specifically, our results indicate that W5 of Vif forms a critical tripartite interaction with I55 and F68 of CBFβ. Substitution of any one of these three residues almost completely abolished the binding of Vif to CBFβ, as determined in Co-IP assays. Mutation of W5 of Vif abolished Vif’s ability to induce degradation of A3G, and mutants of CBFβ with substitutions at the I55 and F68 positions failed to rescue Vif’s function when the endogenous CBFβ was depleted by siRNA knockdown. Our results confirm a previous study indicating that F68D mutation of CBFβ abrogated Vif–CBFβ interaction without affecting the formation of the CBFβ-RUNX1 heterodimer , and other studies [16, 18] which indicated that Vif amino acids 5WQVMIVW11 are important for CBFβ binding. Unlike the previous studies, which performed deletion and substitution mutation analysis in the absence of a structure, we performed a rational, structure-based systematic analysis to map the amino acid determinants that are functionally critical for Vif–CBFβ interaction. Importantly, our results indicate that the W5 of the 5WQVMIVW11 is critical for CBFβ binding and participates in a tripartite interaction with CBFβ residues I55 and F68, while other amino acids make minor contributions to CBFβ binding. We also showed that residues of a disordered loop of CBFβ (amino acids 73–78 of loop 3), which are not modeled in the crystal structure due to poorly defined electron density, are dispensable for interactions with Vif.
We found that the other amino acids in the 5WQVMIVW11 motif did contribute to the interaction with CBFβ, but 3 or 4 alanine substitution mutations were required to completely abolish CBFβ binding. The 5WQVMIVW11 forms a β strand that makes β barrel-like interactions with the β2 and β3 strands of CBFβ. Since backbone hydrogen bonds, and not side-chain bonds, are critical for formation of β barrels, it is possible that multiple alanine substitutions are required to alter the secondary structure of this motif, resulting in loss of interaction with CBFβ.
Our results indicated that Vif amino acids E45–S52 played a role in Vif–CBFβ binding. The exact mechanism by which these Vif residues contribute to the interaction with CBFβ is not clear. We mutated CBFβ residues W73–R78, which are not resolved in the pentameric structure  and are part of the previously reported CBFβ deletion mutant (amino acids 69–90) that abrogated its binding to HIV-1 Vif . Our double-alanine substitution study showed that these CBFβ residues did not significantly contribute to Vif binding. Our results likely differ because the previous study analyzed a larger deletion compared to the region analyzed in our study (amino acids 69–90 vs. 75–81). The deletion most likely affected the overall structure of CBFβ, which resulted in loss of Vif binding; the double-alanine substitution mutants analyzed in our study did not have an effect on the structure of CBFβ and did not affect Vif binding. Thus, Vif residues E45–S52 do not compose a bona fide CBFβ interaction site; it is possible that substitution mutations of Vif residues E45–S52 may have indirectly affected the structure of Vif, resulting in a weaker interaction between W5 and I55 or F68. Although it was not discussed previously, we noted a potential electrostatic interaction between CBFβ E54 and Vif K50. Interestingly, CBFβ E54 is adjacent to I55, which is involved in the tripartite interaction; disruption of a potential electrostatic interaction between Vif K50 and CBFβ E54 may have indirectly influenced the I55 residue position, leading to a weaker binding to Vif.
The results of these studies indicate that Vif–CBFβ and Vif-APOBEC3 interaction surfaces do not overlap and are mutually exclusive. Mutations in the 14DRMR17 and 40YRHHY44 motifs, which were previously shown to be essential for degradation of A3F and A3G, respectively, did not have any effect on the Vif–CBFβ interaction. We also found that several Vif amino acids, including H27, H28, W38, and others are likely to be involved in a hydrophobic interaction that is essential for maintaining the structure of the α-domain of Vif and are not directly involved in interaction with CBFβ. These results are consistent with prior mutagenesis studies .
Results of prior mutagenesis studies [19, 23, 24] and the current study on the effect of residues H27, H28, W38, T47, N48, P49, K50, I57, P58, and F112 mutants of Vif on binding to CBFβ and APOBEC3 proteins can be interpreted and grouped into those that participate in an extensive hydrophobic interaction and those that maintain the structure of the α-domain of Vif. Previous studies found that the W21A mutant was unable to bind to CBFβ [5, 6, 17, 18], while our studies indicate that the W21A–K22A double mutant does not have any apparent defect in CBFβ binding. Examination of the pentameric crystal structure shows that the W21 residue of Vif is buried within the α-domain motif of Vif and does not interact with CBFβ; SASA for W21 is 6.49 Å2. Thus, the W21A mutation most likely results in a major structural change in the α-domain of Vif, resulting in loss of binding to CBFβ. Interestingly, our results suggest that the lysine residue at the 22 position is required for the structural changes induced by the W21A mutation.
The pentameric structure of Vif in complex with CBFβ suggests other potential interactions between Vif and CBFβ. Vif residues W89 is close to CBFβ residue F143, and Vif Y94 is in close proximity to CBFβ I102, E135, D136, and Q140. In addition, Vif C-terminal residues near F115 are in close proximity to CBFβ residue F153 and other residues between 151 and 156. Although these interactions likely stabilize Vif–CBFβ binding, they are not sufficient to retain Vif activity, since mutations at W5 of Vif, or I55 and/or F68 of CBFβ were sufficient to almost completely inhibit Vif’s ability to bind to CBFβ and induce A3G degradation. Although these interactions are not sufficient to support Vif function, additional studies are needed to determine whether other mutations at these sites can result in steric hindrance and interfere with Vif–CBFβ binding. Similarly, the functional significance of Vif–Cul5 and Vif–EloC interactions described in the pentameric structure should be determined to establish whether these interactions may be valuable targets for development of small molecule inhibitors.
Our results provide detailed insight into the critical determinants of the interaction interface between the N-terminus of Vif and CBFβ and identified a tripartite interaction that plays a major role in Vif–CBFβ binding. Together with the available structural data on Vif–CBFβ–E3 ubiquitin ligase complex, these results further our understanding of the biology of HIV-1 Vif–CBFβ interaction and may aid in the development of novel therapeutics that target the Vif–CBFβ interaction and inhibit Vif-mediated degradation of A3 proteins.
Plasmids and cell lines
Expression plasmids of Flag-A3G, HIV-1 Vif and its N-terminal double-alanine substitution mutants, HIV-1 vector HDV-eGFP, and VSV-G expression plasmid phCMV-G were previously described [19, 25–31]. All Vif mutants were generated by site-directed mutagenesis using a QuickChange Lightening site-directed mutagenesis kit (Agilent Technologies) and verified by sequencing. The Flag-CBFβ expression plasmid was obtained from Addgene.
HeLa-derived reporter TZM-bl and 293T cell lines were maintained in DMEM (Corning Cellgro) supplemented with 10% fetal bovine serum (HyClone) and 1% penicillin–streptomycin (GIBCO).
Co-immunoprecipitation assays and western blotting
Flag Co-IP assays were carried out as previously described [19, 25]. Briefly, 293T cells were seeded at 4 × 106 cells per 10-cm dish and transfected the next day by the polyethylenimine PEI method [19, 32]. The following DNA amounts were used to transfect 293T cells: 4 μg Flag-CBFβ, 4 μg Vif, and 1.8 μg pGreen Lantern-1 (pGL) (GIBCO; control for transfections) expression plasmids. To maintain equivalent DNA amounts, pcDNA3.1 was used when needed. After 48 h, total cell lysates were harvested in 1 mL of lysis buffer and Co-IP was performed as previously described [19, 25]. To detect eluted complexes as well as the input cell lysates, western blotting was performed. CBFβ was detected using a rabbit anti-Flag polyclonal antibody (Sigma) at a 1:2000 dilution, Vif was detected using a mouse anti-Vif monoclonal antibody [Clone 319] (ab66643; Abcam) at a 1:2000 dilution, and tubulin as loading control was detected using mouse anti-tubulin antibody (Sigma) at a 1:20,000 dilution. Rabbit and mouse primary antibodies were detected using 1:5000 dilutions of an IRDye® 800CW-labeled goat anti-rabbit secondary antibody (Licor) or an IRDye® 680-labeled goat anti-mouse secondary antibody (Licor). Protein bands were visualized and quantified using an Odyssey® Infrared Imaging System (Licor).
A3G degradation assays
Human 293T cells were seeded at 8 × 105 cells per well in six-well plates and transfections were carried out using the PEI method. To assay for Vif-mediated degradation of A3G, the following plasmids and amounts were used: 0.34 and 0.67 μg of pFlag-A3G, 2.5 μg of Vif, and 0.2 μg pGL (used as a positive control for transfection). To maintain equivalent DNA amount, pcDNA3.1 was added as needed. After 48 h, cell lysates were harvested and immunoblotting analyses were performed to detect steady-state expression levels of A3G in the absence or presence of Vif. Flag-A3G was detected using a rabbit anti-Flag polyclonal antibody (Sigma). HIV-1 Vif, endogenous CBFβ and tubulin were probed as described above.
To produce virus, 293T cells were seeded at 8 × 105 cells per well in six-well plates, and transfected using the PEI method with the following plasmids and amounts: 1 μg of pHDV-eGFP, 0.25 μg of phCMV-G, 0.34 μg or 0.67 μg of pFlag-A3G, and 2.5 μg of Vif. To produce virus with or without CBFβ depletion, 293T cells were seeded at 2.5 × 105 cells per well in six-well plates a day before transfection and the Lipofectamine2000 transfection method (Invitrogen) was used with the following plasmids and amounts: 1 μg of pHDV-eGFP, 0.25 μg of phCMV-G, 0.34 μg or 0.67 μg of pFlag-A3G, and 2.5 μg of Vif in combination with the specific siRNA as described below. After 48 h, the virus-containing supernatants were filtered through 0.45-μm filter and kept at −80 °C until use.
TZM-bl cells were seeded in 96-well plates (4 × 103 cells per well) and were infected the next day in triplicate with viruses normalized for p24 as determined by p24 ELISA (XpressBio). Forty-eight hours later, luciferase activity was determined by britelite™ plus kit (PerkinElmer) following the instructions of the manufacturer using a LUMIstar Galaxy luminometer or 1450 MicroBeta JET (PerkinElmer).
For CBFβ knockdown experiments, 293T cells were seeded at 2.5 × 105 cells per well in six-well plates a day before transfection. Small interfering RNA (siRNA)-mediated transient knockdown of CBFβ was performed using Silencer select CBFβ siRNA targeting coding region (Ambion; S2470) or siRNA-B07 targeting 3′-UTR region (Invitrogen; NM_022845.2_stealth_865), which was designed based on an shRNA described previously  and control siRNA at 25 nM using Lipofectamine RNAiMax reagent (Invitrogen) following the manufacturer instructions. Twenty-four hours later the cells were co-transfected with the respective siRNA (25 nM) and expression plasmids of Flag-A3G, Vif, VSV-G, and HDV-eGFP vector using Lipofectamine2000 reagent in order to produce virus for infectivity (see above for details of the amounts of plasmids used) and maintain efficient CBFβ knockdown. In some CBFβ overexpression rescue experiments, in addition to the above co-transfection cocktails of plasmids, we added either wild-type or different mutants (I55A, I55D, F68A, F68D, I55A-F68D, or I55D-F68D) of CBFβ expression plasmids and carried out infectivity and A3G degradation assays as described above. After 48 h, producer cell lysates and supernatants were collected for western blotting and infectivity assays, respectively.
BAD and VKP designed experiments; BAD and JLS performed experiments; BAD, JLS, HM, WSH, and VKP discussed data; and BAD and VKP wrote the manuscript. All authors read and approved the final manuscript.
We sincerely thank Stephen Hughes, Eric Freed, Krista Delviks-Frankenberry, Ryan Burdick, and Jonathan Rawson for critical comments during manuscript preparation.
The authors declare that they have no competing interests.
This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the U.S. Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol. 2014;426(6):1220–45.View ArticlePubMedGoogle Scholar
- Stavrou S, Ross SR. APOBEC3 proteins in viral immunity. J Immunol. 2015;195(10):4565–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003;302(5647):1056–60.View ArticlePubMedGoogle Scholar
- Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, et al. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature. 2012;481(7381):371–5.Google Scholar
- Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature. 2012;481(7381):376–9.Google Scholar
- Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol. 2009;9(2):106–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Zagami CJ, Zusso M, Stifani S. Runx transcription factors: lineage-specific regulators of neuronal precursor cell proliferation and post-mitotic neuron subtype development. J Cell Biochem. 2009;107(6):1063–72.View ArticlePubMedGoogle Scholar
- Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20(4):723–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, et al. CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell. 2013;49(4):632–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H, et al. Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature. 2014;505(7482):229–33.View ArticlePubMedGoogle Scholar
- Ai Y, Ma J. Multiple lysines combined in HIV-1 Vif determines the responsiveness to CBF-β. Biochem Biophys Res Commun. 2015;457(3):385–90.View ArticlePubMedGoogle Scholar
- Zhou X, Evans SL, Han X, Liu Y, Yu X-F. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS ONE. 2012;7(3):e33495.View ArticlePubMedPubMed CentralGoogle Scholar
- Salter JD, Lippa GM, Belashov IA, Wedekind JE. Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry. 2012;51(44):8702–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Hultquist JF, McDougle RM, Anderson BD, Harris RS. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces. AIDS Res Hum Retroviruses. 2012;28(12):1543–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, et al. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor β. J Virol. 2013;87(3):1906–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Fribourgh JL, Nguyen HC, Wolfe LS, Dewitt DC, Zhang W, Yu XF, et al. Core binding factor β plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J Virol. 2014;88(6):3309–19.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou X, Han X, Zhao K, Du J, Evans SL, Wang H, et al. Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression. J Virol. 2014;88(5):2555–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Matsui Y, Shindo K, Nagata K, Io K, Tada K, Iwai F, et al. Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis. Virology. 2014;449:82–7.View ArticlePubMedGoogle Scholar
- Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol. 2007;81(15):8201–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, et al. Global landscape of HIV-human protein complexes. Nature. 2012;481(7381):365–70.Google Scholar
- Luo Y, Jacobs EY, Greco TM, Mohammed KD, Tong T, Keegan S, et al. HIV-host interactome revealed directly from infected cells. Nat Microbiol. 2016;1(7):16068.View ArticlePubMedPubMed CentralGoogle Scholar
- Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418(6898):646–50.View ArticlePubMedGoogle Scholar
- Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 2005;1(1):e6.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang H, Liu B, Liu X, Li Z, Yu XF, Zhang W. Identification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppression. PLoS ONE. 2014;9(5):e95738.View ArticlePubMedPubMed CentralGoogle Scholar
- Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol. 2009;83(4):1992–2003.View ArticlePubMedGoogle Scholar
- Smith JL, Pathak VK. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol. 2010;84(24):12599–608.View ArticlePubMedPubMed CentralGoogle Scholar
- Smith JL, Izumi T, Borbet TC, Hagedorn AN, Pathak VK. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants. J Virol. 2014;88(17):9893–908.View ArticlePubMedPubMed CentralGoogle Scholar
- Nguyen KL, Ilano M, Akari H, Miyagi E, Poeschla EM, Strebel K, et al. Codon optimization of the HIV-1 Vpu and Vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology. 2004;319(2):163–75.View ArticlePubMedGoogle Scholar
- Yee JK, Friedmann T, Burns JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 1994;43 Pt A:99–112.View ArticlePubMedGoogle Scholar
- Unutmaz D, Kewal Ramani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med. 1999;189(11):1735–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Chaipan C, Smith JL, Hu WS, Pathak VK. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol. 2013;87(1):444–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92(16):7297–301.View ArticlePubMedPubMed CentralGoogle Scholar